Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Is ticagrelor worth its high cost and side-effects?

Abstract : Ticagrelor is a reversible P2Y(12) receptor antagonist that is more potent than clopidogrel. When used in combination with aspirin, it reduces cardiovascular events in patients with acute coronary syndrome. However, unbiased review of 5 randomised controlled trials indicates that although statistically significant, the clinical superiority of ticagrelor over clopidogrel is modest. Thus, identification of patients who benefit the most from ticagrelor is a priority. Besides bleeding issues, ticagrelor can frequently cause bouts of dyspnoea, which requires ticagrelor replacement by another P2Y(12) receptor antagonist, with a loading dose.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03583843
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : mardi 22 février 2022 - 09:50:16
Dernière modification le : dimanche 28 août 2022 - 17:16:25

Identifiants

Collections

Citation

Raphaelle-Ashley Guerbaai, Indrajeet Mahata, Sylvestre Marechaux, Thierry H. Le Jemtel, Pierre-Vladimir Ennezat. Is ticagrelor worth its high cost and side-effects?. Acta Cardiologica, Acta Medica Belgica, 2019, 74 (2), pp.93-98. ⟨10.1080/00015385.2018.1469371⟩. ⟨hal-03583843⟩

Partager

Métriques

Consultations de la notice

7